Open AccessPhase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer
Author(s) -
Mitchell E. Gross,
David B. Agus,
Tanya B. Dorff,
Jacek Pinski,
David I. Quinn,
Olga O. Castellanos,
Patrick Gilmore,
Jean C. Shih
Publication year - 2020
Publication title -
prostate cancer and prostatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2
H-Index - 64
eISSN - 1476-5608
pISSN - 1365-7852
DOI - 10.1038/s41391-020-0211-9
Subject(s) - phenelzine , medicine , prostate cancer , gastroenterology , urology , cancer , monoamine oxidase , biochemistry , chemistry , enzyme
Monoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine oxidase inhibitor) in patients with biochemical recurrent castrate-sensitive prostate cancer.